Lupin receives Final FDA Approval for Trandolapril

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, June 14, 2007 - Lupin Ltd. announced today that the US FDA has granted Final approval for the Company's Abbreviated New Drug Application (ANDA) for Trandolapril Tablets, 1mg, 2mg and 4mg. Commercial shipments of the product have commenced.

Lupin's Trandolapril Tablets are the AB-rated generic equivalent of Abbott's Mavik® Tablets, indicated for the treatment of hypertension. The brand product had annual sales of approximately $49 million for the twelve months ended December 2006, based on IMS sales data.

"We are delighted with the timely approval of Trandolapril tablets. This approval broadens our growing portfolio of cardiovascular medications," said Dr. Kamal Sharma, Managing Director, Lupin.

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2007, Lupin's Revenues and Profit after Tax were Rs.20,289 million (US$ 475 million) and Rs. 3,021 million (US$ 70 million) respectively.

For further information contact:

Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com